Personalized Combination Therapies for Progeroid Diseases and Cellular Aging

A next-generation platform for treating laminopathies, cellular aging, and atherosclerosis, leveraging genomics, machine learning, and nanotechnology to provide personalized, targeted, and adaptive combination therapies.

The original patent disclosed combination therapies for progeroid diseases and conditions, but had limitations in terms of generic treatment approaches and lack of personalized medicine. The new inventive concept addresses these limitations by integrating genomics, machine learning, and nanotechnology to provide tailored treatment regimens, thereby improving efficacy and reducing side effects.

The new inventive concept comprises a genomics-based diagnostic module, a machine learning-based therapeutic module, and a nanotechnology-based delivery module. The diagnostic module identifies a subject's genetic predisposition to progeroid diseases, while the therapeutic module selects a customized combination of farnesyltransferase inhibitors and mTOR inhibitors based on the subject's genetic profile. The delivery module administers the selected therapeutic combination in a targeted and sustained manner using nanoparticles. Additionally, the platform includes a digital health module for remotely monitoring the subject's response to the treatment and adjusting the regimen accordingly.

The new claims introduce a paradigm shift in the treatment of laminopathies, cellular aging, and atherosclerosis by incorporating genomics, machine learning, and nanotechnology. The integration of these technologies enables personalized medicine, targeted delivery, and adaptive treatment regimens, which are not anticipated by the original patent.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, various nanoparticle designs, or the incorporation of additional therapeutic agents. Variations of the platform could be developed for specific disease indications or patient populations, ensuring broad conceptual coverage.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of personalized medicine, rare genetic diseases, and age-related disorders. The platform's adaptability and potential for remote monitoring and treatment adjustment also open up opportunities in the digital health and telemedicine sectors.